OTCPK:GNBT (USA) Also trade in: Germany

Generex Biotechnology Corp

$ 1.18 -0.02 (-1.67%)
Volume: 17,870 Avg Vol (1m): 96,647
Market Cap $: 71.24 Mil Enterprise Value $: 138.71 Mil
P/E (TTM): 2.31 P/B: 0.00
Earnings Power Value -12.64
Net Current Asset Value -1.54
Tangible Book -1.51
Projected FCF -0.82
Median P/S Value 20.46
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 2/10

Current vs industry vs history
Cash-to-Debt 0.05
Equity-to-Asset -0.21
Debt-to-Equity -2.71
Debt-to-EBITDA 1.55
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -6.66
DISTRESS
GREY
SAFE
Beneish M-Score 3.75
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC -21.94%

Profitability & Growth : 4/10

Current vs industry vs history
Operating Margin % -177.76
Net Margin % 465.90
ROA % 102.26
ROC (Joel Greenblatt) % 9119.58

» GNBT's 30-Y Financials

Financials (Next Earnings Date: )

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with OTCPK:GNBT

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare XSAT:ALTE OTCPK:TIKRF NZSE:PIL LSE:AOR ASX:ACL TSXV:PBS XSAT:INIT XCNQ:PREV XSAT:SLOTT B OTCPK:CAPS WAR:BLR XSAT:PANION OSTO:ANNX TSXV:MFS XSAT:PMED OTCPK:STLT OTCPK:MTST OTCPK:NULF OTCPK:SGBI TSXV:IOT
Traded in other countries GB8A.Germany
Address 10102 USA Today Way, Miramar, FL, USA, 33025
Generex Biotechnology Corp is a US-based Biotechnology company which is primarily engaged in the research and development of drug delivery systems and technologies. It mainly focuses on developing technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. The company operates in the single segment being the Research and development of drug delivery systems and technologies for metabolic and immunological diseases. In addition, the company engages in developing proprietary vaccine formulations through its subsidiaries that work by stimulating the immune system to either attack offending agents that is cancer cells, bacteria, and viruses or to stop attacking benign elements.

Ratios

Current vs industry vs history
PE Ratio (TTM) 2.31
PE Ratio without NRI 2.31
Price-to-Owner-Earnings 2.20
PS Ratio 12.69
EV-to-EBIT 5.32
EV-to-EBITDA 5.24
EV-to-Revenue 26.87
Current Ratio 0.10
Quick Ratio 0.08
Days Inventory 50.01
Days Sales Outstanding 174.37

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -9.00

Valuation & Return

Current vs industry vs history
Price-to-Median-PS-Value 0.06
Earnings Yield (Joel Greenblatt) % 18.80

More Statistics

Revenue (TTM) (Mil) $ 5.16
EPS (TTM) $ 0.51
Beta -4.91
Volatility % 350.89
52-Week Range $ 0.08 - 3.1
Shares Outstanding (Mil) 60.36

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA Y
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA N
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y